Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1991 1
1993 3
1994 10
1995 3
1996 7
1997 6
1998 9
1999 23
2000 19
2001 17
2002 18
2003 22
2004 29
2005 26
2006 21
2007 27
2008 27
2009 26
2010 30
2011 24
2012 16
2013 18
2014 21
2015 16
2016 16
2017 11
2018 17
2019 7
2020 16
2021 21
2022 21
2023 2
Text availability
Article attribute
Article type
Publication date

Search Results

496 results
Results by year
Filters applied: . Clear all
Page 1
Parkinson's Disease: From Pathogenesis to Pharmacogenomics.
Cacabelos R. Cacabelos R. Int J Mol Sci. 2017 Mar 4;18(3):551. doi: 10.3390/ijms18030551. Int J Mol Sci. 2017. PMID: 28273839 Free PMC article. Review.
Conventional pharmacological treatments for PD are dopamine precursors (levodopa, l-DOPA, l-3,4 dihidroxifenilalanina), and other symptomatic treatments including dopamine agonists (amantadine, apomorphine, bromocriptine, cabergoline, lisuride, pergolide, pramipexole, ropinirole, …
Conventional pharmacological treatments for PD are dopamine precursors (levodopa, l-DOPA, l-3,4 dihidroxifenilalanina), and other symptomati …
Levodopa/carbidopa/entacapone for the treatment of early Parkinson's disease: a meta-analysis.
Liao X, Wu N, Liu D, Shuai B, Li S, Li K. Liao X, et al. Neurol Sci. 2020 Aug;41(8):2045-2054. doi: 10.1007/s10072-020-04303-x. Epub 2020 Mar 11. Neurol Sci. 2020. PMID: 32162166 Review.
Treatment of Parkinson's disease with levodopa/carbidopa/entacapone (LCE) has been studied for a long time. However, the efficacy and safety of LCE in the treatment of early Parkinson's disease (PD) still need to be assessed. ...PubMed, Embase, the Cochrane Library, and th …
Treatment of Parkinson's disease with levodopa/carbidopa/entacapone (LCE) has been studied for a long time. However, the efficacy and …
Drugs for Parkinson's disease.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2021 Feb 22;63(1618):25-32. Med Lett Drugs Ther. 2021. PMID: 33647001 Review. No abstract available.
Entacapone alleviates acute kidney injury by inhibiting ferroptosis.
Yang J, Sun X, Huang N, Li P, He J, Jiang L, Zhang X, Han S, Xin H. Yang J, et al. FASEB J. 2022 Jul;36(7):e22399. doi: 10.1096/fj.202200241RR. FASEB J. 2022. PMID: 35691001
We demonstrated that entacapone prevents renal I/R injury by inhibiting ferroptosis. Compared with a sham group, entacapone treatment mitigated I/R-induced pathological alterations, improved renal function, and inhibited ferroptosis. ...Entacapone may serve a …
We demonstrated that entacapone prevents renal I/R injury by inhibiting ferroptosis. Compared with a sham group, entacapone tr …
Comparison chart: Drugs for Parkinson's disease.
[No authors listed] [No authors listed] Med Lett Drugs Ther. 2020 Dec 14;62(1613):e1-e9. Med Lett Drugs Ther. 2020. PMID: 33647002 Review. No abstract available.
Dopaminergic Therapy for Motor Symptoms in Early Parkinson Disease Practice Guideline Summary: A Report of the AAN Guideline Subcommittee.
Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, de Bie RMA, Roze E, Miyasaki JM, Hauser RA, Espay AJ, Martello JP, Gurwell JA, Billinghurst L, Sullivan K, Fitts MS, Cothros N, Hall DA, Rafferty M, Hagerbrant L, Hastings T, O'Brien MD, Silsbee H, Gronseth G, Lang AE; Guideline Subcommittee of the AAN. Pringsheim T, et al. Neurology. 2021 Nov 16;97(20):942-957. doi: 10.1212/WNL.0000000000012868. Neurology. 2021. PMID: 34782410 Free PMC article. Review.
The comparison of different formulations of dopamine agonists yielded little evidence that any one formulation or method of administration is superior. Long-acting forms of levodopa and levodopa with entacapone do not appear to differ in efficacy from immediate-release lev …
The comparison of different formulations of dopamine agonists yielded little evidence that any one formulation or method of administration i …
Entacapone.
Chong BS, Mersfelder TL. Chong BS, et al. Ann Pharmacother. 2000 Sep;34(9):1056-65. doi: 10.1345/aph.19328. Ann Pharmacother. 2000. PMID: 10981253 Review.
OBJECTIVE: To introduce entacapone, a new catechol-O-methyltransferase inhibitor, and discuss its pharmacology, pharmacodynamics, pharmacokinetics, clinical efficacy, drug interactions, adverse events, dosage guidelines, and therapeutic and formulary considerations. …
OBJECTIVE: To introduce entacapone, a new catechol-O-methyltransferase inhibitor, and discuss its pharmacology, pharmacodynamics, pha …
Targeted Inhibition of FTO Demethylase Protects Mice Against LPS-Induced Septic Shock by Suppressing NLRP3 Inflammasome.
Luo J, Wang F, Sun F, Yue T, Zhou Q, Yang C, Rong S, Yang P, Xiong F, Yu Q, Zhang S, Wang CY, Li J. Luo J, et al. Front Immunol. 2021 May 4;12:663295. doi: 10.3389/fimmu.2021.663295. eCollection 2021. Front Immunol. 2021. PMID: 34017338 Free PMC article.
We herein show that nanoparticle-mediated Fto-siRNA delivery or FTO inhibitor entacapone administration dramatically inhibited macrophage activation, reduced the tissue damage and improved survival in a mouse model of LPS-induced endotoxic shock. ...
We herein show that nanoparticle-mediated Fto-siRNA delivery or FTO inhibitor entacapone administration dramatically inhibited macrop …
Entacapone.
Müller T. Müller T. Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):983-93. doi: 10.1517/17425255.2010.502167. Expert Opin Drug Metab Toxicol. 2010. PMID: 20572781 Review.
The addition of the catechol-O-methyltransferase inhibitor entacapone (EN) to LD/carbidopa (CD) improves wearing off, as EN prolongs LD half-life and avoids troughs. ...
The addition of the catechol-O-methyltransferase inhibitor entacapone (EN) to LD/carbidopa (CD) improves wearing off, as EN prolongs …
COMT Inhibitors in the Management of Parkinson's Disease.
Fabbri M, Ferreira JJ, Rascol O. Fabbri M, et al. CNS Drugs. 2022 Mar;36(3):261-282. doi: 10.1007/s40263-021-00888-9. Epub 2022 Feb 25. CNS Drugs. 2022. PMID: 35217995 Review.
Currently, two peripheral COMT-Is are considered as first-line choices - entacapone (ENT), which was approved by the US Food and Drug Administration in 1999 and the European Committee in 1998; and opicapone (OPC), which was approved by the European Committee in 2016. ...
Currently, two peripheral COMT-Is are considered as first-line choices - entacapone (ENT), which was approved by the US Food and Drug …
496 results